Clinical Trials

36 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05348811 2026-01-06

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Phase 2 Completed

25 enrolled

Cholangiocarcinoma

NCT05171166 2025-12-18

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Phase 2/3 Terminated

18 enrolled

Carcinoma, Hepatocellular

NCT07157306 2025-09-05

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

35 enrolled

Carcinoma, Hepatocellular

NCT06685289 2025-01-28

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

Phase 2 Recruiting

70 enrolled

Biliary Malignant Tumors

NCT06609876 2024-12-03

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Phase NA Recruiting

108 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT06581315 2024-09-03

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

Phase NA Recruiting

204 enrolled

Carcinoma, Hepatocellular

NCT05262959 2024-08-13

A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC

Phase 2 Completed

Carcinoma, Hepatocellular

NCT06512467 2024-07-22

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT06498622 2024-07-12

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Phase 2 Recruiting

45 enrolled

Carcinoma, Hepatocellular

NCT05576909 2023-07-13

Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation

20 enrolled

Carcinoma, Hepatocellular

NCT04962958 2023-06-22

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Carcinoma, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

NCT02489201 2023-06-15

A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Phase 1/2 Terminated

19 enrolled

Esophageal Neoplasms

NCT02870582 2022-11-29

Donafenib for Previously Treated Metastatic Colorectal Cancer

Phase 3 Completed

536 enrolled

Colorectal Neoplasms

NCT05350943 2022-10-18

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

70 enrolled

Biliary Tract Adenocarcinoma

NCT05545124 2022-09-19

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

32 enrolled

Carcinoma, Hepatocellular

NCT05507632 2022-08-19

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

48 enrolled

Carcinoma, Hepatocellular

NCT05493332 2022-08-18

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

93 enrolled

Carcinoma, Hepatocellular

NCT05166772 2021-12-22

Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT05161143 2021-12-17

Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT05138159 2021-11-30

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

10 enrolled

Pancreatic Neoplasms

NCT04979663 2021-08-09

GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

Phase 1/2 Unknown

10 enrolled

Biliary Tract Carcinoma

NCT02489916 2016-01-05

Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer

Phase 1/2 Completed

47 enrolled